Synaptogenix (SNPX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for neurological disorders driven by synaptic dysfunction. The company’s proprietary platform centers on small molecules engineered to modulate key signaling pathways in neurons, with the goal of enhancing synaptogenesis and neuroprotection. By targeting central nervous system pathways, Synaptogenix seeks to address unmet needs in diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis and other neurodegenerative conditions.

The company’s lead product candidate is a synthetically optimized analog of bryostatin, a marine-derived compound known to activate protein kinase C (PKC) pathways. Preclinical studies have shown that this candidate promotes synaptic growth, supports neuronal survival and may improve cognitive function. Synaptogenix is advancing this program through early- to mid-stage clinical trials in patients with mild to moderate Alzheimer’s disease, while also exploring additional indications across a range of neurodegenerative and neuroinflammatory disorders.

Headquartered in Birmingham, Alabama, Synaptogenix maintains strategic collaborations with academic institutions, research hospitals and contract research organizations across North America and Europe. These partnerships underpin multi-center clinical studies and enable efficient conduct of both human trials and preclinical research. The company’s facilities support Good Manufacturing Practice (GMP) production of clinical trial material as well as ongoing discovery and development activities.

Founded in 2008, Synaptogenix is guided by a leadership team composed of seasoned executives and scientific advisors with extensive backgrounds in neuroscience, drug development and regulatory affairs. Drawing on experience from major pharmaceutical and biotechnology firms, the management team is committed to executing a robust development strategy. Synaptogenix aims to translate its synaptic modulation platform into safe and effective treatments that may improve quality of life for patients suffering from debilitating neurological diseases.

Key Stats

• Today's Range: $7.60 to $9.00
• 50-Day Range: $2.16 to $8.50
• 52-Week Range: $1.84 to $7.85
• Volume: 998,620 shs
• Average Volume: 243,781 shs
• Market Capitalization: $12.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Synaptogenix Stock Analysis - MarketRank™

Synaptogenix scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Synaptogenix.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Synaptogenix is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synaptogenix is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synaptogenix has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.63% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently increased by 1,419.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synaptogenix does not currently pay a dividend.

Dividend Growth

Synaptogenix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.63% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently increased by 1,419.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Synaptogenix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Synaptogenix this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for SNPX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synaptogenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.73% of the stock of Synaptogenix is held by insiders.

Percentage Held by Institutions

Only 10.34% of the stock of Synaptogenix is held by institutions.

SNPX Stock Analysis - Frequently Asked Questions

How have SNPX shares performed this year?

Synaptogenix's stock was trading at $3.47 at the beginning of the year. Since then, SNPX shares have increased by 159.1% and is now trading at $8.99.

How were Synaptogenix's earnings last quarter?

Synaptogenix, Inc. (NASDAQ:SNPX) released its quarterly earnings data on Thursday, May, 15th. The company reported $0.04 earnings per share (EPS) for the quarter.

When did Synaptogenix's stock split?

Shares of Synaptogenix reverse split on the morning of Friday, April 5th 2024.The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Synaptogenix?

Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synaptogenix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synaptogenix investors own include SoFi Technologies (SOFI), Fluence Energy (FLNC), The9 (NCTY), Riot Platforms (RIOT), PubMatic (PUBM), Clean Energy Fuels (CLNE) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNPX
• CIK: 1571934
• Web: www.synaptogen.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($10.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.28%
• Return on Assets: -58.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 72.59
• Quick Ratio: 72.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 1,390,000
• Free Float: 1,352,000
• Market Cap: $12.50 million
• Optionable: Not Optionable
• Beta: 1.08